Research at Oslo University Hospital


Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.


Latest news

Gathering Friday October 28th 10-12 at UiO:

Announcement of research funding from the Norwegian Cancer Society


The board of the Norwegian Cancer Society will October 24th decide which research projects that will be funded. All applications have been peer reviewed internationally. Those receiving funding will be contacted prior to the event.
The announcement event take place on Friday October 28th at 10-10 AM in the "Professorboligen" at the University of Oslo. There will be talks held by a scientist, a fund-raiser, and a personal story will be told. There will also be an artistic peformance, and refreshments will be served.

Final date for registration: October 25th


Dag Berild awarded the "Akademikerprisen" for his work on antibiotic resistance

Dag Berild
Dag Berild

Dag Berild from the Department of Infectious Diseases at the Division of Medicine has recently been awarded the "Akademikerprisen".
Berild receives the prize for his important work within the field of antibiotic resistance, which is considered one of the major global Health threats of today.
The "Akademikerprisen" will be distributed during the Akademikernes fall Meeting October 27th. Berild will here receive a sculpture from the artist Nico Widerberg and a sum amounting to 100.000 NOK.


Making therapeutic antibodies from scratch

Mouldy Sioud<br>Senior author
Mouldy Sioud
Senior author

Mouldy Sioud (photo) from the Department of Immunology at the Instiute for Cancer Research is senior author on an article recently published in Oncotarget (journal impact factor 6.36), entitled "Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth".


Lina Prasmickaite's work presented in popularised form

Lina Prasmickaite
Lina Prasmickaite

Lina Prasmickaite from the Department of Tumor Biology at the Institute for Cancer Research has spent several years studying why certain cancer cells become immune against treatment. Her research on this subject is presented in a popular science article (in Norwegian) recently published by the Norwegian Cancer Society.


Focus on personalized medicine and the MetAction study

Gunhild Mælandsmo (left) and Kjersti Flatmark
Gunhild Mælandsmo (left) and Kjersti Flatmark

The Norwegian Cancer Society have recently published a popular science article (in Norwegian) presenting the work of Gunhild Mælandsmo and Kjersti Flatmark, both from the Department of Tumor Biology at the Institute for Cancer Research. The scientists explains how their research on colorectal cancer may improve the methods of personalized medicine, and how the MetAction study, which is supported by the Norwegian Cancer Society, may contribute to the development of more precise cancer treatments in the future.


Paper from Dahl/Klungland published in the Sep 22nd issue of Nature

Histone marks regulate maternal-to-zygotic transition

John Arne Dahl<br>First author
John Arne Dahl
First author

John Arne Dahl (photo), from Department of Microbiology has published a collaborative study entitled "Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition", in the 22nd September issue of Nature (journal impact factor 41.5).

The study was carried out together with the lab of Arne Klungland, Department of Microbiology, and Bing Ren, University of California and Ludwig Institute for Cancer Research, San Diego.

The findings are also covered in a news article on the web site of the Ludwig Institute for Cancer Research.


Marina Vietri interviewed for major Italian research web portal

Marina Vietri (photo ResearchItaly)
Marina Vietri (photo ResearchItaly)

A comprehensive interview with postdoc Marina Vietri from Harald Stenmark's group at the Department of Molecular Biology has recently been published on - the web portal of the Italian Ministry of Education, University and Research (MIUR) established in order to map, support and promote high-quality Italian research.
The introduction to the English version of this readable interview goes as follows: "From San Raffaele in Milan to the Institute for Cancer Research of the University Hospital of Oslo where her research deserved publication in Nature and she won the Norwegian H.M. the King’s Gold medal for best PhD thesis in Medicine in the year 2016, being the first Italian researcher who has ever received it."


OUH researchers publish groundbreaking computer tools for cell biology research in Nature Methods


A group at the Department of Immunology at OUH has developed software tools that help solving one of the biggest challenges in large-scale protein analysis, or proteomics. In an article published in prestigious Nature Methods (journal impact factor 32.1) they show that Microsoft Excel can be applied to align large datasets from multiple studies and obtain a better picture of how cells are wired.


POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis

Ragnhild A. Lothe and Arild Nesbakken
Ragnhild A. Lothe and Arild Nesbakken

A multicentre biomarker study, including data from the research teams of professors Ragnhild A. Lothe and Arild Nesbakken at the K.G.Jebsen Colorectal Cancer Research Centre, OUH, was recently published in Lancet Gastroenterology & Hepatology.
A small subgroup of patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POLE) proofreading are shown to have excellent prognosis.


Clinical Cancer Research highlights biomarker paper from Lyng’s group

Christina Sæten Fjeldbo (first author)
Christina Sæten Fjeldbo (first author)

Molecular targeting of tumor hypoxia is a promising strategy for improving the radiotherapy of cervical cancer. A biomarker for classifying patients according to hypoxia is, however, lacking and is an important requirement for reliable drug evaluation and to avoid added toxicity to patients with no expected benefit.
In a study published in Clinical Cancer Research (journal impact factor 8.7), postdoc Christina S. Fjeldbo (photo) in Lyng’s group and colleagues at Oslo University Hospital and Aarhus University Hospital present a hypoxia classifier that is reflected in diagnostic DCE-MR images and based on the expression level of six genes in a biopsy.